The Preclinical Evaluation of Immunocontraceptive Vaccines Based on Canine Zona Pellucida 3 (cZP3) in a Mouse Model

Overview

Journal Reprod Biol Endocrinol

Publisher Biomed Central

Specialties Endocrinology
Reproductive Medicine

Date 2018 May 13

PMID 29751768

Citations 2

Authors

Ying Wang

Yijie Li

Beibei Zhang

Fuchun Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Stray dogs are the reservoirs and carriers of rabies and are definitive hosts of echinococcosis. To control the overpopulation of stray dogs, zona pellucida 3 (ZP3), a primary receptor for sperm, is a potential antigen for developing contraceptive vaccines. To enhance the immune responses and contraceptive effects of canine ZP3 (cZP3), dog gonadotropin-releasing hormone (GnRH) and a T cell epitope of chicken ovalbumin (OVA) were selected to construct two fusion proteins with cZP3, ovalbumin-GnRH-ZP3 (OGZ) and ovalbumin-ZP3 (OZ), and their contraceptive effects were evaluated in mice.

Methods: The synthesized DNA sequences of OGZ and OZ were cloned into plasmid pET-28a respectively. The fusion proteins OGZ and OZ were identified by SDS-PAGE and Western blot. Mice were immunized with OGZ, OZ and cZP3, and the infertility rates were monitored. Mice immunized with mouse ZP3 (mZP3) or adjuvant alone were used as positive control and negative control, respectively. cZP3- and GnRH-specific antibodies (Abs) were detected by ELISA. The bindings of the Abs to oocytes were detected by indirect immunofluorescence assay. The paraffin sections of mice ovaries were observed under microscope for analyzing pathological characteristics.

Results: SDS-PAGE and Western blot analyses showed that the two fusion proteins OGZ and OZ were correctly expressed. ELISA results showed that OGZ vaccine induced both cZP3- and GnRH-specific Abs, and OZ vaccine induced cZP3-specific Ab, which lasted for up to 168 days. The levels of follicle stimulating hormone (FSH) and estradiol (E2) in sera were significantly decreased in OGZ immunized mice. Indirect immunofluorescence results showed that Abs induced by cZP3 and mZP3 could bind to the mouse ZP and dog ZP each other. Compared with the adjuvant group, all vaccine immunized groups significantly decreased the fertility rate and mean litter size. Interestingly, the fertility rate in OGZ-immunized group is the lowest, and only 1 mouse out of 10 mice is fertile. Histological analysis of murine ovarian sections indicated that most of the infertile mice in the immunized groups lacked mature follicles as well as accompanied by inflammatory infiltration. Meanwhile, immunization with OGZ decreased the number of corpora lutea in the infertile mice.

Conclusions: The fusion protein OGZ resulted in the lowest fertility rate and the least mean litter size in the immunized mice. OGZ might be a promising antigen for developing a new contraceptive vaccine for stray dog controlling.

Citing Articles

Progesterone Promotes In Vitro Maturation of Domestic Dog Oocytes Leading to Successful Live Births.

Qin Y, Feng S, Zheng M, Liu X, Zhao J, Zhao Q Life (Basel). 2022; 12(11).

PMID: 36362933 PMC: 9698205. DOI: 10.3390/life12111778.

Immunocontraceptive potential of a GnRH receptor-based fusion recombinant protein.

Sandam N, Prakash D, Thimmareddy P J Genet Eng Biotechnol. 2021; 19(1):63.

PMID: 33945047 PMC: 8096874. DOI: 10.1186/s43141-021-00164-9.

References

Liu Y, Tian Y, Zhao X, Jiang S, Li F, Zhang Y . Immunization of dogs with recombinant GnRH-1 suppresses the development of reproductive function. Theriogenology. 2014; 83(3):314-9. DOI: 10.1016/j.theriogenology.2014.06.029. View

Levy J, Miller L, Crawford P, Ritchey J, Ross M, Fagerstone K . GnRH immunocontraception of male cats. Theriogenology. 2004; 62(6):1116-30. DOI: 10.1016/j.theriogenology.2003.12.025. View

Bauer A, Lacorn M, Danowski K, Claus R . Effects of immunization against GnRH on gonadotropins, the GH-IGF-I-axis and metabolic parameters in barrows. Animal. 2012; 2(8):1215-22. DOI: 10.1017/S1751731108002346. View

Bleil J, Wassarman P . Mammalian sperm-egg interaction: identification of a glycoprotein in mouse egg zonae pellucidae possessing receptor activity for sperm. Cell. 1980; 20(3):873-82. DOI: 10.1016/0092-8674(80)90334-7. View

Killian G, Miller L, Rhyan J, Doten H . Immunocontraception of Florida feral swine with a single-dose GnRH vaccine. Am J Reprod Immunol. 2006; 55(5):378-84. DOI: 10.1111/j.1600-0897.2006.00379.x. View

Robbins S, Jelinski M, Stotish R . Assessment of the immunological and biological efficacy of two different doses of a recombinant GnRH vaccine in domestic male and female cats (Felis catus). J Reprod Immunol. 2004; 64(1-2):107-19. DOI: 10.1016/j.jri.2004.08.004. View

McNeilly A, Jonassen J, Fraser H . Suppression of follicular development after chronic LHRH immunoneutralization in the ewe. J Reprod Fertil. 1986; 76(1):481-90. DOI: 10.1530/jrf.0.0760481. View

Kitchener A, Harman A, Kay D, McCartney C, Mate K, Rodger J . Immunocontraception of Eastern Grey kangaroos (Macropus giganteus) with recombinant brushtail possum (Trichosurus vulpecula) ZP3 protein. J Reprod Immunol. 2009; 79(2):156-62. DOI: 10.1016/j.jri.2008.10.004. View

Brunius C, Zamaratskaia G, Andersson K, Chen G, Norrby M, Madej A . Early immunocastration of male pigs with Improvac(®) - effect on boar taint, hormones and reproductive organs. Vaccine. 2011; 29(51):9514-20. DOI: 10.1016/j.vaccine.2011.10.014. View

10.

Monnier-Barbarino P, Forges T, Faure G, Bene M . [Ovarian autoimmunity and ovarian pathologies: antigenic targets and diagnostic significance]. J Gynecol Obstet Biol Reprod (Paris). 2005; 34(7 Pt 1):649-57. DOI: 10.1016/s0368-2315(05)82897-2. View

11.

MacKenzie S, McLaughlin E, Perkins H, French N, Sutherland T, Jackson R . Immunocontraceptive effects on female rabbits infected with recombinant myxoma virus expressing rabbit ZP2 or ZP3. Biol Reprod. 2005; 74(3):511-21. DOI: 10.1095/biolreprod.105.046268. View

12.

Shrestha A, Wadhwa N, Gupta S . Evaluation of recombinant fusion protein comprising dog zona pellucida glycoprotein-3 and Izumo and individual fragments as immunogens for contraception. Vaccine. 2013; 32(5):564-71. DOI: 10.1016/j.vaccine.2013.11.078. View

13.

Jungnickel M, Sutton K, Wang Y, Florman H . Phosphoinositide-dependent pathways in mouse sperm are regulated by egg ZP3 and drive the acrosome reaction. Dev Biol. 2007; 304(1):116-26. PMC: 1892180. DOI: 10.1016/j.ydbio.2006.12.023. View

14.

Miller L, Gionfriddo J, Fagerstone K, Rhyan J, Killian G . The single-shot GnRH immunocontraceptive vaccine (GonaCon) in white-tailed deer: comparison of several GnRH preparations. Am J Reprod Immunol. 2008; 60(3):214-23. DOI: 10.1111/j.1600-0897.2008.00616.x. View

15.

Chambers R, Johnston S . High-level generation of polyclonal antibodies by genetic immunization. Nat Biotechnol. 2003; 21(9):1088-92. DOI: 10.1038/nbt858. View

16.

Dalin A, Andresen O, Malmgren L . Immunization against gnRH in mature mares: antibody titres, ovarian function, hormonal levels and oestrous behaviour. J Vet Med A Physiol Pathol Clin Med. 2002; 49(3):125-31. DOI: 10.1046/j.1439-0442.2002.00427.x. View

17.

Tung K, Agersborg S, Bagavant H, Garza K, Wei K . Autoimmune ovarian disease induced by immunization with zona pellucida (ZP3) peptide. Curr Protoc Immunol. 2008; Chapter 15:Unit 15.17. DOI: 10.1002/0471142735.im1517s49. View

18.

Henderson C, Braude P, Aitken R . Polyclonal antibodies to a 32-kDa deglycosylated polypeptide from porcine zonae pellucidae will prevent human gamete interaction in vitro. Gamete Res. 1987; 18(3):251-65. DOI: 10.1002/mrd.1120180306. View

19.

Minhas V, Shrestha A, Wadhwa N, Singh R, Gupta S . Novel Sperm and Gonadotropin-releasing Hormone-based Recombinant Fusion Protein: Achievement of 100% Contraceptive Efficacy by Co-immunization of Male and Female Mice. Mol Reprod Dev. 2016; 83(12):1048-1059. DOI: 10.1002/mrd.22743. View

20.

Jinshu X, Jingjing L, Duan P, Zheng Z, Ding M, Jie W . A synthetic gonadotropin-releasing hormone (GnRH) vaccine for control of fertility and hormone dependent diseases without any adjuvant. Vaccine. 2005; 23(40):4834-43. DOI: 10.1016/j.vaccine.2005.05.010. View